全文获取类型
收费全文 | 12025篇 |
免费 | 780篇 |
国内免费 | 477篇 |
专业分类
耳鼻咽喉 | 25篇 |
儿科学 | 113篇 |
妇产科学 | 24篇 |
基础医学 | 471篇 |
口腔科学 | 192篇 |
临床医学 | 1618篇 |
内科学 | 2352篇 |
皮肤病学 | 438篇 |
神经病学 | 51篇 |
特种医学 | 434篇 |
外科学 | 1427篇 |
综合类 | 2440篇 |
预防医学 | 453篇 |
眼科学 | 352篇 |
药学 | 1620篇 |
19篇 | |
中国医学 | 1167篇 |
肿瘤学 | 86篇 |
出版年
2024年 | 17篇 |
2023年 | 227篇 |
2022年 | 253篇 |
2021年 | 355篇 |
2020年 | 350篇 |
2019年 | 288篇 |
2018年 | 272篇 |
2017年 | 352篇 |
2016年 | 362篇 |
2015年 | 368篇 |
2014年 | 785篇 |
2013年 | 968篇 |
2012年 | 766篇 |
2011年 | 798篇 |
2010年 | 657篇 |
2009年 | 569篇 |
2008年 | 556篇 |
2007年 | 547篇 |
2006年 | 530篇 |
2005年 | 508篇 |
2004年 | 397篇 |
2003年 | 352篇 |
2002年 | 303篇 |
2001年 | 371篇 |
2000年 | 281篇 |
1999年 | 230篇 |
1998年 | 229篇 |
1997年 | 191篇 |
1996年 | 184篇 |
1995年 | 168篇 |
1994年 | 155篇 |
1993年 | 112篇 |
1992年 | 104篇 |
1991年 | 96篇 |
1990年 | 94篇 |
1989年 | 77篇 |
1988年 | 86篇 |
1987年 | 74篇 |
1986年 | 45篇 |
1985年 | 35篇 |
1984年 | 30篇 |
1983年 | 23篇 |
1982年 | 17篇 |
1981年 | 19篇 |
1980年 | 19篇 |
1979年 | 13篇 |
1978年 | 12篇 |
1977年 | 12篇 |
1976年 | 10篇 |
1975年 | 7篇 |
排序方式: 共有10000条查询结果,搜索用时 78 毫秒
1.
Diabetic foot ulcer is a devastating complication of diabetes mellitus and significant cause of mortality and morbidity all over the world and can be complex and costly. The development of foot ulcer in a diabetic patient has been estimated to be 19%-34% through their lifetime. The pathophysiology of diabetic foot ulcer consist of neuropathy, trauma and, in many patients, additional peripheral arterial disease. In particular, diabetic neuropathy leads to foot deformity, callus formation, and insensitivity to trauma or pressure. The standard algorithms in diabetic foot ulcer management include assessing the ulcer grade classification, surgical debridement, dressing to facilitate wound healing, off-loading, vascular assessment (status and presence of a chance for interventional vascular correction), and infection and glycemic control. Although especially surgical procedures are sometimes inevitable, they are poor predictive factors for the prognosis of diabetic foot ulcer. Different novel treatment modalities such as nonsurgical debridement agents, oxygen therapies, and negative pressure wound therapy, topical drugs, cellular bioproducts, human growth factors, energy-based therapies, and systematic therapies have been available for patients with diabetic foot ulcer. However, it is uncertain whether they are effective in terms of promoting wound healing related with a limited number of randomized controlled trials. This review aims at evaluating diabetic foot ulcer with regard to all aspects. We will also focus on conventional and novel adjunctive therapy in diabetic foot management. 相似文献
2.
Bacterial keratitis continues to be one of the leading causes of corneal blindness in the developed as well as the developing world, despite swift progress since the dawn of the “anti-biotic era”. Although, we have expeditiously developed our understanding about the different causative organisms and associated pathology leading to keratitis, extensive gaps in knowledge continue to dampen the efforts required for early and accurate diagnosis, and management in these patients, resulting in poor clinical outcomes. The ability of the causative bacteria to subdue the therapeutic challenge stems from their large genome encoding complex regulatory networks, variety of unique virulence factors, and rapid secretion of tissue damaging proteases and toxins.In this review article, we provide an overview of the established diagnostic techniques and therapeutics for keratitis caused by various bacteria. We extensively report the recent in-roads through novel tools for accurately diagnosing mono- and poly-bacterial corneal infections. Furthermore, we outline the recent progress by our groups and others in understanding the sub-cellular genomic changes that lead to antibiotic resistance in these organisms. Finally, we discuss in detail, the novel therapies and drug delivery systems in development for the efficacious management of bacterial keratitis. 相似文献
3.
4.
Effect of Yinqi Ointment on Wound Morphology and Growth
Factor in Treating Diabetic Foot Ulcer 下载免费PDF全文
Objective: To investigate the effect of Yinqi ointment on wound morphology and growth factor in treating diabetic foot ulcer(DFU).Methods: From December 2016 to December 2017, 92 cases of DFU with deficiency of both Qi and Yin syndrome were randomly divided into treatment group and control group(44 cases in each group). The treatment group was treated with Yinqi ointment, while the control group was treated with mupirocin ointment. After 4 weeks of treatment, the ulcer healing effect, ulcer area, granulation tissue, epithelial tissue coverage,pain score, and dynamic analysis of vascular endothelial growth factor(VEGF), epidermis growth factor(EGF), and basic fibroblast growth factor(bFGF) in local granulation tissue were statistically analyzed before and after treatment in both groups. Results: The total effective rate was 88.37% in the treatment group and 74.42% in the control group. The wound reduction rate, epithelial tissue coverage rate, granulation tissue growth rate, and local pain relief rate in the treatment group were significantly superior to those in the control group(P 0.05). Through the local granulation detection, the treatment group and the control group have increased VEGF, EGF, and bFGF, but the treatment group increased the role of growth factor than the control group. Conclusion: Yinqi ointment can promote the healing of DFU, and its mechanism may be related to the increase of the content of growth factor in granulation tissue. 相似文献
5.
目的分析治疗口疮的成方制剂的剂型、功能主治、组方用药规律及核心组合,为临床治疗口疮的辨证用药及新药研发提供参考。方法 收集《中华人民共和国卫生部药品标准·中药成方制剂》(以下简称《中药成方制剂》)、《中华人民共和国药典:2015年版》(以下简称2015年版《中国药典》)中治疗口疮的成方制剂的名称、处方、剂型、功能与主治,录入Microsoft Excel及中医传承辅助平台(V2.5),统计用药频次;运用Apriori算法及关联规则对处方核心组合进行统计分析(支持度为10%,置信度100%);采用熵聚类算法统计2-3个不同成分间的关联系数(支持度为8,惩罚度为2);根据无监督的熵层次聚类法提取内在核心组合和新方组合。结果 挖掘得出86种成方制剂及其处方,以丸剂、散剂、片剂等多见,包含药物148味,使用频次较高为冰片、甘草、大黄、黄芩等,药物四气五味以苦寒为主,主要归肺胃心脾经,治疗证型较多为热毒炽盛证、热毒攻喉证等,常用核心配伍包括“黄芩-大黄”“黄连-甘草”等,挖掘得出新方组合“珍珠-川贝母-灯心草-天花粉-没药”等4首。结论 利用数据挖掘分析治疗口疮的成方制剂的组方规律,由核心药物组合成新方,可为临床辨证使用及研发治疗口疮成方制剂、新药提供依据和参考。 相似文献
6.
《Annales de dermatologie et de vénéréologie》2021,148(4):228-232
BackgroundVenous leg ulcers (VLUs) often take a very long time to heal. Timolol maleate has been reported as displaying efficacy in healing of VLUs.ObjectivesTo evaluate the efficacy of timolol maleate gel in the management of hard-to-heal VLUs and to assess its safety as a topical agent during 12 weeks of use in combination with conventional treatment.MethodsA prospective, phase-II randomised-controlled trial with a sample size based on Fleming's one-stage design (P0 = 0.25, P1 = 0.45, alpha = 0.1, beta = 0.2) was planned. Patients with VLUs present for ≥ 24 weeks and with ≥ 50% granulation tissue were included. One drop of sustained-release timolol gel (Timoptol® LP 0.5%, Santen, Tampere, Finland) per 6 cm2 VLU area was applied every 2 days for 12 weeks in timolol-treated patients, as adjuvant therapy to the standard care protocol (interface dressing and multilayer venous compression). Controls received standard care alone. The primary endpoint was to obtain ≥ 40% reduction in ulcer area at week 12 (W12).ResultsForty-three patients were randomised to the study, with 40 receiving at least one treatment and included in the analysis: 21 timolol-treated patients and 19 controls (females: 70%; median age: 72.5 [range 35–93] years). At W12, ≥ 40% ulcer-area reduction was achieved in 14/21 (67%) timolol-treated patients vs. 6/19 (32%) controls. No serious adverse events occurred. Local wound infections not requiring systemic antibiotics occurred in 5 cases in the timolol group and in one case in the controls.ConclusionsThese results support the benefit and safety of using timolol maleate to manage hard-to-heal VLUs, but confirmation is required in a larger multicentre randomised phase-III study. 相似文献
7.
Michelle Y L Tang Patrick H Y Chung Hau Y Chan Paul K H Tam Kenneth KY Wong 《Journal of pediatric surgery》2019,54(2):255-257
Objective
Helicobacter pylori infection is common among Asians. However, evidence in the recent years has demonstrated a decrease in the prevalence of H. pylori infection among children and adults worldwide. Our aim was to update its prevalence in symptomatic children in our locality in the recent 12?years and compared to the results of our previous review published in 2005.Methods
A retrospective review was carried out between 2005 and 2017. All children who presented with dyspepsia or gastrointestinal bleeding and underwent oesophagogastroduodenoscopy with antral biopsy taken were included. Patient demographics, endoscopic, or histological diagnosis and the H. pylori status were recorded.Main Results
A total of 602 patients were included. There was a statistically significant decreasing trend of H. pylori infection rate between 2005 and 2017 (p?=?0.003). The overall infection rate from this study was 12.8%, compared to 25.6% from our previous review. Overall failure of eradication with first-line antibiotic therapy has increased to 29.3% from 10% in our previous review.Conclusion
There was a decrease in the prevalence of H. pylori infection among symptomatic children for the recent 12?years, comparing to our previous data from 2005. We hypothesize that the reduction in prevalence of H. pylori infection among adults and the decrease in the practice of sharing chopsticks during meals have led to a decrease in transmission of the bacteria among family members in Hong Kong. However, the failure of eradication with first line treatment was higher, possibly due to the increase in antibiotics usage and resistance.Level of Evidence
III 相似文献8.
Michelle Lerman Julia A. Gaebler Sunday Hoy Jessica Izhakoff Laura Gullett Timothy Niecko Pinar Karaca-Mandic Thomas ODonnell Stanley G. Rockson 《Journal of vascular surgery》2019,69(2):571-580
Objective
Phlebolymphedema (chronic venous insufficiency-related lymphedema) is a common and costly condition. Nevertheless, there is a dearth of evidence comparing phlebolymphedema therapeutic interventions. This study sought to examine the medical resource utilization and phlebolymphedema-related cost associated with Flexitouch (FLX; Tactile Medical, Minneapolis, Minn) advanced pneumatic compression devices (APCDs) relative to conservative therapy (CONS) alone, simple pneumatic compression devices (SPCDs), and other APCDs in a representative U.S. population of phlebolymphedema patients.Methods
This was a longitudinal matched case-control analysis of deidentified private insurance claims. The study used administrative claims data from Blue Health Intelligence for the complete years 2012 through 2016. Patients were continuously enrolled for at least 18 months, diagnosed with phlebolymphedema, and received at least one claim for CONS either alone or in addition to pneumatic compression (SPCDs or APCDs). The main outcomes included direct phlebolymphedema- and sequelae-related medical resource utilization and costs.Results
After case matching, the study included 86 patients on CONS (87 on FLX), 34 on SPCDs (23 on FLX), and 69 on other APCDs (67 on FLX). Compared with CONS, FLX was associated with 69% lower per patient per year total phlebolymphedema- and sequelae-related costs net of any pneumatic compression device-related costs ($3839 vs $12,253; P = .001). This was driven by 59% fewer mean annual hospitalizations (0.13 vs 0.32; P < .001) corresponding to 82% lower inpatient costs and 55% lower outpatient hospital costs. FLX was also associated with 52% lower outpatient physical therapy and occupational therapy costs and 56% lower other outpatient-related costs. Compared with SPCDs, FLX was associated with 85% lower total costs ($1153 vs $7449; P = .008) driven by 93% lower inpatient costs ($297 vs $4215; P = .002), 84% lower outpatient hospital costs ($368 vs $2347; P = .020), and 85% lower other outpatient-related costs ($353 vs $2313; P = .023). Compared with APCDs, FLX was associated with 53% lower total costs ($3973 vs $8436; P = .032) because of lower outpatient costs and lower rates of cellulitis (22.4% vs 44.9% of patients; P = .02).Conclusions
This analysis indicates significant benefits attributable to FLX compared with alternative compression therapies that can help reduce the notable economic burden of phlebolymphedema. 相似文献9.
10.
目的观察双歧杆菌三联活菌胶囊联合四联疗法治疗幽门螺杆菌(Hp)所致胃溃疡的效果。方法选取2016年1月至2019年12月在郑州大学附属郑州中心医院治疗的112例Hp所致胃溃疡患者为研究对象。按照随机数字表法分为对照组与观察组,每组56例。对照组采取四联疗法(雷贝拉唑钠+胶体果胶铋+克拉霉素+阿莫西林)治疗;观察组在对照组基础上,联合双歧杆菌三联活菌胶囊治疗。比较两组患者的临床疗效、Hp根除率、不良反应及复发率。结果观察组患者的治疗总有效率(98.21%,55/56)高于对照组(85.71%,48/56),差异有统计学意义(P<0.05)。观察组患者的Hp根除率(92.96%,52/56)高于对照组(76.79%,43/56),观察组复发率(3.57%,2/56)低于对照组(16.07%,9/56),差异均有统计学意义(P<0.05)。结论联合应用双歧杆菌三联活菌胶囊、四联疗法可提高治疗效果及Hp根除率,减少病情复发,且安全性良好。 相似文献